CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

Yuan Gao; Li-rong Zhang; Qiang Fu

首页> 外文期刊>European Journal of Clinical Pharmacology >CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

【24h】

CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

机译：CYP3A4 * 1G基因多态性与阿托伐他汀的降脂功效相关，与辛伐他汀的降脂功效无关

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose Our aim was to observe the impact of CYP3A4*1G genetic polymorphism on lipid-lowering efficacy of statins.

机译：目的我们的目的是观察CYP3A4 * 1G基因多态性对他汀类药物降脂功效的影响。

著录项

来源
《European Journal of Clinical Pharmacology》 |2008年第9期|p.877-882|共6页
作者
Yuan Gao; Li-rong Zhang; Qiang Fu;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
CYP3A4; Polymorphisms; Simvastatin; Atorvastatin; Lipid; lowering efficacy;

机译：CYP3A4;多态性;辛伐他汀;阿托伐他汀;脂质;降低功效;

相似文献

外文文献
中文文献
专利

1. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. [J] . Gao Y, Zhang LR, Fu Q European journal of clinical pharmacology . 2008,第9期

机译：CYP3A4 * 1G多态性与阿托伐他汀的降脂功效有关，与辛伐他汀的降脂功效无关。
2. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients [J] . An Wang, Bang-Ning Yu, Chen-Hui Luo, European Journal of Clinical Pharmacology . 2005,第12期

机译：CYP3A4基因Ile118Val基因多态性及其对辛伐他汀降脂疗效的影响
3. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. [J] . Fiegenbaum M, da Silveira FR, Van der Sand CR, Clinical Pharmacology and Therapeutics . 2005,第5期

机译：ABCB1，CYP3A4和CYP3A5基因的常见变体在辛伐他汀治疗的降脂功效和安全性中的作用。
4. PCSK9 polymorphism rs505151 affects lipid-lowering response to atorvastatin but does not influence ezetimibe therapy in Chilean subjects [C] . Zambrano T, Caama?o JM, Rosales A, International Congress on Coronary Artery Disease . 2011

机译：PCSK9多态性RS505151影响到阿托伐他汀的降脂响应，但不会影响智利受试者的ezetimibe治疗
5. An Examination of the Fate, Transport, and Occurrence of Atorvastatin and Simvastatin in Wastewater Treatment Systems. [D] . Ottmar, Karl Joseph. 2010

机译：阿托伐他汀和辛伐他汀在废水处理系统中的命运，运输和发生情况的检查。
6. Effect of CYP3A4∗1G and CYP3A5∗3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects [O] . Shuaibing Liu, Xiangfen Shi, Xin Tian, 2017

机译：CYP3A4 * 1G和CYP3A5 * 3基因多态性对替卡格雷的药代动力学和药效学的影响
7. Effect of CYP3A4∗1G and CYP3A5∗3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects [O] . Shuaibing Liu, Xiangfen Shi, Xin Tian, 2017

机译：CYp3a4 * 1G和CYp3a5 * 3基因多态性对替卡格雷在中国健康人群中的药代动力学和药效学的影响

CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

摘要

著录项

相似文献

相关主题

期刊订阅